Corvus Pharmaceuticals: A New Immunotherapy Player

| April 4, 2018

article image
The immune checkpoints are signaling molecules that act to shut down or block an immune response. In a healthy person, this mechanism is a "safety" feature allowing cessation of the immune response once it has performed its task. Cytotoxic T Lymphocyte Antigen 4 (CTLA‐4) and programmed Death 1 (PD1) are the most well‐known checkpoints, but there are many others. Tumor cells have evolved to use these checkpoints to inhibit an immune response, but agents like Yervoy (anti-CTLA-4) and Opdivo or Keytruda (both anti-PD1) have the potential to unleash the immune system's cancer-destroying properties. FDA and EMA approve all of them, but preclinical data suggest that there are many other immune checkpoints or targets that may be modulated to promote an immune response.

Spotlight

Pharma Focus Asia

Pharma Focus Asia is a half yearly publication from Ochre Media Pvt. Ltd.. It is the leading pharma title in print and digital versions serving the information needs of key executives from the world’s leading pharmaceutical companies.

OTHER ARTICLES

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | February 11, 2020

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

The Future of Pharma Beyond Blockbusters

Article | March 17, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

5 Pharma Trends and Their Impact on Packaging

Article | February 27, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

Spotlight

Pharma Focus Asia

Pharma Focus Asia is a half yearly publication from Ochre Media Pvt. Ltd.. It is the leading pharma title in print and digital versions serving the information needs of key executives from the world’s leading pharmaceutical companies.

Events